Mohan Bala
Corporate Officer/Principal bij MERSANA THERAPEUTICS, INC.
Vermogen: 62 953 $ op 31-03-2024
Profiel
Mohan Bala's career history includes current and former positions as well as education.
Currently, Dr. Bala is the Chief Development Officer & Senior Vice President at Mersana Therapeutics, Inc. Prior to this, Dr. Bala held the position of Chief Operating Officer at Constellation Pharmaceuticals, Inc. and Vice President of Lead Development Program at Tesaro, Inc. Dr. Bala's education includes an MBA and a doctorate from The University of Chicago.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
16-01-2024 | 14 052 ( 0.01% ) | 62 953 $ | 31-03-2024 |
Actieve functies van Mohan Bala
Bedrijven | Functie | Begin |
---|---|---|
MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 25-10-2021 |
Eerdere bekende functies van Mohan Bala
Bedrijven | Functie | Einde |
---|---|---|
TESARO INC | Corporate Officer/Principal | - |
CONSTELLATION PHARMACEUTICALS, INC. | Chief Operating Officer | - |
Opleiding van Mohan Bala
The University of Chicago | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MERSANA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |